Xilio Therapeutics, Inc. (XLO)
$9.22+1.65%Close
BUYBEAR · day 35
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $61M
- Beta
- -0.12
- P/E (TTM)
- -6.19
- Short % float
- 17.41%
- Days to cover
- 44.5
- SI change
- -0.7%
- 1W
- +2.44%
- 1M
- +3.25%
- vs SPY 1W
- +2.58%
- vs SPY 1M
- +0.74%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 15
- VALUE
- 16
- GROWTH
- 47
- GARP
- 8
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-30.5%
REV YoY-
ROE-50.8%
EPS YoY-
ROA-14.2%
GROSS99
OP-49
NET-34
[VALUATION]
P/E TTM-6.19
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.48
P/FCF-
EV/EBITDA3.37
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E8.72
ALTMAN Z-
CURR RATIO4.25
ND/EBITDA-
BETA-0.12
Company news
FAQ
- What is LOPJLB’s current signal on XLO?
- LOPJLB’s latest quantitative signal on Xilio Therapeutics, Inc. (XLO) is BUY in a BEAR regime. Signals are updated daily.
- What market regime is XLO in?
- Xilio Therapeutics, Inc. (XLO) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Xilio Therapeutics, Inc. (XLO) do?
- Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, includ…